All In Biotech

Drug Trial Radar · NCT02638103

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,890 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,890

Actual

Start

Feb 26, 2016

Primary completion

Jun 6, 2018

Study completion Dec 8, 2018

Sponsor

Sponsor type
Industry
First posted
Dec 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC) administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic migraine (EM). Participants with CM or EM who complete the pivotal efficacy studies of TEV-48125 (TV48125-CNS-30049 \[NCT02621931\] and TV48125-CNS-30050 \[NCT02629861\]) and agree to participate in this study; and new participants meeting eligibility criteria (not rolling over from pivotal studies), will be enrolled in this study.

Conditions

  • Migraine

Interventions

  • FremanezumabDrug

    Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

  • PlaceboDrug

    Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Baseline (Day 0) up to follow-up visit (Day 533)
  2. Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry ResultsTime frame: Baseline (Day 0) up to end of treatment (EOT) visit (Day 336)
  3. Number of Participants With Potentially Clinically Significant Abnormal Hematology ResultsTime frame: Baseline (Day 0) up to EOT visit (Day 336)
  4. Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests ResultsTime frame: Baseline (Day 0) up to EOT visit (Day 336)
  5. Number of Participants With Potentially Clinically Significant Abnormal Vital Signs ValuesTime frame: Baseline (Day 0) up to EOT visit (Day 336)
  6. Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) ParametersTime frame: Baseline (Day 0), endpoint (Day 336)
  7. Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test ResultsTime frame: Baseline (Day 0), endpoint (Day 336)
  8. Number of Participants With Injection Site ReactionsTime frame: Baseline (Day -28 to Day -1), Month 12
  9. Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)Time frame: Baseline (Day -28 to Day -1), Month 12

Locations

139 sites in 9 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 13628

    Birmingham, Alabama

  • Teva Investigational Site 13577

    Birmingham, Alabama

  • Teva Investigational Site 13606

    Phoenix, Arizona

  • Teva Investigational Site 13579

    Phoenix, Arizona

  • Teva Investigational Site 13602

    Little Rock, Arkansas

  • Teva Investigational Site 13568

    Encino, California

  • Teva Investigational Site 13546

    Fullerton, California

  • Teva Investigational Site 13540

    Long Beach, California

  • Teva Investigational Site 13632

    Redlands, California

  • Teva Investigational Site 13571

    Redondo Beach, California

  • Teva Investigational Site 13573

    San Diego, California

  • Teva Investigational Site 13538

    Santa Monica, California

  • Teva Investigational Site 13594

    Santa Rosa, California

  • Teva Investigational Site 13595

    Walnut Creek, California

  • Teva Investigational Site 13629

    Aurora, Colorado

  • Teva Investigational Site 13557

    Boulder, Colorado

  • Teva Investigational Site 13593

    Colorado Springs, Colorado

  • Teva Investigational Site 13633

    Denver, Colorado

  • Teva Investigational Site 13612

    Denver, Colorado

  • Teva Investigational Site 13631

    Englewood, Colorado

  • Teva Investigational Site 13563

    East Hartford, Connecticut

  • Teva Investigational Site 13550

    Stamford, Connecticut

  • Teva Investigational Site 13635

    Bradenton, Florida

  • Teva Investigational Site 13597

    Gainesville, Florida

  • Teva Investigational Site 13607

    Hialeah, Florida

  • Teva Investigational Site 13559

    Jacksonville, Florida

  • Teva Investigational Site 13584

    Ocala, Florida

  • Teva Investigational Site 13587

    Orlando, Florida

  • Teva Investigational Site 13567

    Palm Beach Gardens, Florida

  • Teva Investigational Site 13553

    Pembroke Pines, Florida

  • Teva Investigational Site 13616

    Pinellas Park, Florida

  • Teva Investigational Site 13620

    Atlanta, Georgia

  • Teva Investigational Site 13537

    Atlanta, Georgia

  • Teva Investigational Site 13604

    Boise, Idaho

  • Teva Investigational Site 13585

    Chicago, Illinois

  • Teva Investigational Site 13621

    Chicago, Illinois

  • Teva Investigational Site 13627

    Evanston, Illinois

  • Teva Investigational Site 13596

    Indianapolis, Indiana

  • Teva Investigational Site 13617

    Wichita, Kansas

  • Teva Investigational Site 13598

    Wichita, Kansas

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.